SCHEMBL6949381

SCHEMBL6949381

CC(=O)c1ccc(-c2cccnc2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 7/20 0.71
MKNK2 Q9HBH9 7/20 0.71
MAPT P10636 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
CYP3A4 P08684 2/20 0.56
CYP2A6 P11509 2/20 0.56
ALDH1A1 P00352 2/20 0.56
CYP1A2 P05177 1/20 0.56
NPC1 O15118 2/20 0.55
RAB9A P51151 2/20 0.55
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
CYP19A1 P11511 1/20 0.54
CYP11B1 P15538 1/20 0.54
CYP11B2 P19099 1/20 0.54
KIF11 P52732 1/20 0.53
KMO O15229 1/20 0.53
GRM1 Q13255 1/20 0.52
HSD17B1 P14061 1/20 0.52
LMNA P02545 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27605181 0.85 MKNK1 (0.76) MKNK1MKNK2MAPTSMN1; SMN2CYP3A4
SCHEMBL13712389 0.84 CYP11B2 (0.72) MKNK1MKNK2CYP3A4CYP1A2CYP19A1
SCHEMBL18943256 0.84 KMO (0.60) MKNK1MKNK2MAPTSMN1; SMN2CYP3A4
SCHEMBL29788154 0.83 MKNK1 (1.00) MKNK1MKNK2CYP3A4CYP2A6ALDH1A1
SCHEMBL208351 0.83 MKNK1 (1.00) MKNK1MKNK2CYP3A4CYP2A6ALDH1A1
SCHEMBL2277474 0.82 NPC1 (0.66) SMN1; SMN2CYP3A4ALDH1A1CYP1A2NPC1
SCHEMBL4426460 0.82 KMO (0.73) MKNK1MKNK2CYP3A4CYP2A6ALDH1A1
SCHEMBL14621505 0.82 MKNK1 (0.59) MKNK1MKNK2CYP3A4CYP2A6ALDH1A1
SCHEMBL606654 0.81 MKNK1 (1.00) MKNK1MKNK2CYP3A4CYP2A6ALDH1A1
SCHEMBL30855339 0.81 MKNK1 (1.00) MKNK1MKNK2CYP3A4CYP2A6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4573086-A1 METHANOGEN INHIBITORS Agrizeronz Limited Partnership (NZ) 2025-06-25 EP disclosed
CN-119998272-A Methanogen inhibitors 阿格里泽伦茨有限合伙公司 2025-05-13 CN disclosed
WO-2024039250-A1 METHANOGEN INHIBITORS PASTORAL GREENHOUSE GAS RESEARCH LIMITED (NZ) 2024-02-22 WO disclosed
WO-2023091644-A2 HSD17B13-RELATED DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO WAVE LIFE SCIENCES LTD. (SG) 2023-05-25 WO disclosed
US-10784446-B2 Compound, organic electroluminescence element material, organic electroluminescence element and electronic device IDEMITSU KOSAN CO., LTD. (JP) 2020-09-22 US disclosed
CN-110563638-A compound and organic electronic device thereof 上海嵘彩光电材料有限公司 2019-12-13 CN disclosed
CN-109988159-A The diphenylpyrimidin compound and its organic electroluminescent device replaced through pyridine 昱镭光电科技股份有限公司 2019-07-09 CN disclosed
US-20170213983-A1 COMPOUND, ORGANIC ELECTROLUMINESCENCE ELEMENT MATERIAL, ORGANIC ELECTROLUMINESCENCE ELEMENT AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2017-07-27 US disclosed
US-20170213983-A1 COMPOUND, ORGANIC ELECTROLUMINESCENCE ELEMENT MATERIAL, ORGANIC ELECTROLUMINESCENCE ELEMENT AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2017-07-27 US disclosed
US-20130295261-A1 ISOSORBIDE DERIVATIVES AND THEIR USE AS FLAVOR MODIFIERS, TASTANTS, AND TASTE ENHANCERS SENOMYX, INC. (US) 2013-11-07 US disclosed
US-8420145-B2 Isosorbide derivatives and their use as flavor modifiers, tastants, and taste enhancers SENOMYX, INC. (US) 2013-04-16 US disclosed
EP-1802641-B1 BISPHOSPHONATE COMPOUNDS AND METHODS FOR BONE RESORPTION DISEASES, CANCER, BONE PAIN, IMMUNE DISORDERS, AND INFECTIOUS DISEASES UNIV ILLINOIS (US) 2011-08-10 EP disclosed
WO-2010137350-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS 住友化学株式会社 (JP) 2010-12-02 WO disclosed
US-20090220662-A1 ISOSORBIDE DERIVATIVES AND THEIR USE AS FLAVOR MODIFIERS, TASTANTS, AND TASTE ENHANCERS SENOMYX, INC. 2009-09-03 US disclosed
EP-1075475-B1 HETEROCYCLIC CARBOXAMIDE DERIVATIVES AS INHIBITORS OF NITRIC OXIDE PRODUCTION FUJISAWA PHARMACEUTICAL CO (JP) 2003-06-18 EP disclosed
US-20020132809-A1 Heterocyclic carboxamide derivatives as inhibitors of nitric oxide production FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-09-19 US disclosed
EP-1075475-A1 HETEROCYCLIC CARBOXAMIDE DERIVATIVES AS INHIBITORS OF NITRIC OXIDE PRODUCTION FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-02-14 EP disclosed
CN-1056840-C Oxime derivatives, their preparation and their therapeutic use SANKYO CO (JP) 2000-09-27 CN disclosed
WO-1999057114-A1 HETEROCYCLIC CARBOXAMIDE DERIVATIVES AS INHIBITORS OF NITRIC OXIDE PRODUCTION FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020132809-A1 Heterocyclic carboxamide derivatives as inhibitors of nitric oxide production NOS1, NOS3, NOS2 MKNK1 1529/4885MKNK2 1898/4885MAPT 333/4885
US-20090220662-A1 ISOSORBIDE DERIVATIVES AND THEIR USE AS FLAVOR MODIFIERS, TASTANTS, AND TASTE ENHANCERS TAS2R10, TAS2R41, TAS2R30 MKNK1 1636/4885MKNK2 1597/4885MAPT 812/4885
US-10784446-B2 Compound, organic electroluminescence element material, organic electroluminescence element and electronic device L1CAM, SOD1, OR10J3 MKNK1 4120/4885MKNK2 4072/4885MAPT 3405/4885
US-20170213983-A1 COMPOUND, ORGANIC ELECTROLUMINESCENCE ELEMENT MATERIAL, ORGANIC ELECTROLUMINESCENCE ELEMENT AND ELECTRONIC DEVICE L1CAM, SOD1, OR10J3 MKNK1 4120/4885MKNK2 4072/4885MAPT 3405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.